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Abstract 
 
PURPOSE: In our previous phase II study of 5-fluorouracil and cisplatin 
(FP) for advanced gastric cancer, vascular endothelial growth factor (VEGF) 
was a predictor of chemoresponse, and patients having four or five favorable 
phenotypes out of p53 (-), bcl-2 (-), gluthathione S-transferase π (GST- π) (-), 
thymidylate synthase (TS) (-), and VEGF (+) survived longer than those having 
three or less. The purpose of this study is to confirm our previous results and to 
compare the significance of those markers between continuous infusion of 
5-FU (5-FUci) and FP. PATIENTS AND METHODS: The above five markers 
were examined immunohistochemically in pre-treatment biopsy from 131 of 210 
advanced gastric cancer patients (JCOG9205). RESULTS: Median survival 
times (MST) of 65 patients treated with 5-FUci and 66 patients with FP were 
216 and 253 days (p=0.6953). Twenty patients with four or five of the above 
favorable phenotypes survived longer than the other 46 patients with three or 
less in FP (MST: 334, 243 days, p=0.0463). Survival times of 34 and 32 patients 
with VEGF (-) and (+) were similar in FP (MST: 269, 253 days, p=0.6317), 
whereas 30 patients with VEGF (+) survived shorter than 35 patients with VEGF 
(-) in 5-FUci (MST: 142 and 302 days, p=0.0043). CONCLUSION: The number 
of favorable phenotypes was confirmed to be a prognostic factor of gastric 
cancer patients treated with FP, and it is suggested that VEGF might be a 
selective marker between FP and 5-FUci. 
 
Mini-abstract 
 Number of phenotypes of p53(-), bcl-2(-), GST- π (-), TS(-), VEGF(+) 
was a prognostic factor in treatment with FP for gastric cancer, and VEGF might 
be a predictor between FP and 5-FUci. 
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Introduction 
 
Recently, many combination chemotherapy regimens including new 
agents have been developed, and show high response rates for advanced 
gastric cancer (1-8). However, in randomized phase III trials, no regimens have 
been reported indicating survival benefit to treatment with 5-fluorouracil (5-FU) 
alone (9-10), thus no standard chemotherapy has been established for 
advanced gastric cancer. In the phase III study of the Gastrointestinal Oncology 
Study Group in the Japan Clinical Oncology Group (GIOSG/JCOG), there was 
no significant difference in survival between the continuous infusion of 5-FU 
(5-FUci) and a combination of 5-FU and cisplatin (FP), despite a higher 
response rate and longer time to progression (TTP) of FP compared with 
5-FUci, and toxicities of 5-Fuci was lower than FP (11). Therefore, 5-FUci has 
still been recognized as one of the reference regimens for the present phase III 
study of advanced gastric cancer patients. It has also been reported that a good 
response to chemotherapy contributes to a long survival and cure of some 
patients (12) while severe toxicity associated with intensive chemotherapy 
causes deterioration in the patient's quality of life, especially in non-responders. 
Thus, it is very important to predict the effects of chemotherapy and to select an 
appropriate regimen for each patient before the commencement of 
chemotherapy. 
Progress in basic research has revealed many factors and mechanisms 
implicated in sensitivity and resistance to chemotherapy, and some of these 
have been reported as having clinical impacts (13-16). However, there have 
been no reports of biological markers that are clearly useful for selecting 
chemotherapy regimens of advanced gastric cancer patients. In our previous 
study along the phase II study of FP for advanced gastric cancer, vascular 
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endothelial growth factor (VEGF) (+), p53 (-), bcl-2 (-), thymidylate synthase 
(TS) (-), and gluthathione S-transferase π (GST-  π) (-) were shown to be 
favorable phenotypes for chemoresponses in 39 patients (17). Of these, 
patients with VEGF (+) showed a significantly higher response rate than those 
with VEGF (-). However, there was no difference in survival times between 
patients with (+) and (-) values in any of the above markers individually. There 
was a clear relationship between the number of favorable phenotypes and the 
response rates, and the 10 patients with four or five favorable phenotypes 
survived significantly longer than the 29 patients with three or fewer. 
However, since our previous study was investigational, these results 
should be confirmed in another cohort. Moreover, the clinical utility of these 
markers for selecting chemotherapy regimens should be investigated and 
compared in a randomized phase III trial. 
In this paper, we investigate the relationship between the expressions 
of the above five biological markers and the survival effects among the patients 
registered in the phase III study (JCOG9205 (11)) to confirm the results of our 
previous study, and to clarify the utility of these markers in selecting the 
chemotherapy regimens 5-FUci or FP. This study was approved by the chair of 
the Japan Clinical Oncology Group. 
 
 
Patients and Methods 
 
Patients 
The source of the subjects were 280 patients enrolled into the phase III 
study (JCOG9205); 106 patients had been treated with 5-FUci, 104 with FP, 
and 70 with a combination of futrafur and uracil (UFT) plus mitomycin C (UFTM). 
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Biopsy samples were obtained from 180 patients, consisting of 68 (64%) from 
the 5-FUci group, 67 (64%) from the FP group, and 45 (64%) from the UFTM 
group. The 45 patients treated with UFTM were excluded from this study 
because UFTM treatment was stopped after the interim analysis of the phase III 
study had revealed no survival advantage and more severe toxic effects 
compared with 5-FUci (11). Three patients in the 5-FUci group, and one in the 
FP group, were also excluded because their biopsy samples were insufficient 
for immunostaining. Finally, the subjects of this study comprised 65 patients 
treated with 5-FUci and 66 with FP, from whom sufficient amounts of 
pre-treatment biopsy specimens were obtained endoscopically. These patients 
fulfilled the eligibility criteria of JCOG9205: (1) histological confirmation of 
gastric cancer, (2) measurable or assessable lesions, (3) ability to accept oral 
administration of UFT, (4) aged 75 years or younger, (5) a performance status 
of 2 or less on the ECOG scale, (6) no prior treatment except surgery, (7) fully 
functioning liver, kidney, and bone marrow, (8) life expectancy of eight weeks or 
longer, and (9) written informed consent. All the patients in the study received 
the protocol chemotherapy as the first line therapy. 
 
Treatment schedule 
The treatment schedule for the 5-FUci group comprised a continuous 
infusion of 5-FU (800 mg/m2 per day) on days 1 to 5. The FP schedule 
consisted of a drip infusion of CDDP (20 mg/m2 per day) on days 1 to 5, 
together with the same dose of 5-FUci. These two treatments were repeated 
every four weeks until the appearance of disease progression, unacceptable 
toxicity, or the patient's voluntary withdrawal. 
 
Immunohistochemistry 
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The biopsy samples obtained from 180 patients were immunostained 
as described in our previous study (17). All immunohistochemical examinations 
were performed on tissue sections from formalin-fixed and paraffin-embedded 
biopsy materials obtained endoscopically from primary tumors. Serial 3 m 
thick slices were cut, deparaffinized in xylene, and dehydrated with graded 
ethanol, then immersed in methanol with 0.3% H2O2 for 20 minutes to inhibit 
endogenous peroxidase activity. The sections stained for p53 and TS were 
heated to 95 oC by microwave irradiation for 10 minutes in phosphate buffered 
saline (PBS) or 10 mM citrate buffer, respectively.  The sections stained for 
VEGF were treated with 0.05% pepsin in 0.01 N HCl for 20 minutes at room 
temperature. After blocking with 10% normal swine serum in PBS (blocking 
buffer) for 60 minutes, all sections were incubated overnight at room 
temperature with the primary antibodies diluted in blocking buffer to the 
following concentrations: anti-p53 antibody (Nichirei, Tokyo, Japan), 1:20000; 
anti-bcl-2 antibody (DAKO, Glostrup, Denmark), 1:40; anti-GST- π antibody 
(MBL, Nagoya, Japan), 1:24000; anti-TS antibody (TS106 (16)), 1:200; and 
anti-VEGF antibody (Santa Cruz Biochemistry, CA, USA), 1:500. The sections 
were washed with PBS and then incubated for one hour with biotinylated 
secondary antibody diluted to 1:200. After washing with PBS, the sections were 
incubated with ABC reagent (Vector Laboratories, CA, USA), and the color 
reaction was developed in 2% 3-3'-diaminobenzidine and 0.3% hydrogen 
peroxide in Tris buffer. The sections were then counterstained with hematoxylin 
or methyl green. 
All immunostained specimens from the 180 patients were assessed by 
an investigator (N.B.) who was not informed of any clinical informations such as 
treatment schedules and clinical outcomes. The intensity of staining for p53 and 
GST- π was graded as (+) when strong, as (+) when faint, and as (-) when no 
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staining was visible. For bcl-2, the intensity of staining was graded as (++) when 
stronger than that of correspondingly stained lymphocytes, as (+) when equal, 
and as (-) when weaker than that of stained lymphocytes. The staining of VEGF 
was graded as (++) when the intensity of staining in cancer cells was stronger 
than that in stromal cells, as (+) when equal, and as (-) when weaker. TS 
expression was graded as (++), (+), (+), (-) based on the intensity of the 
staining. For all markers, patients were defined as positive when more than 
20% of all cancer cells in each section showed (++) or (+). 
 
Anti-tumor effects 
The responses of measurable metastatic lesions and of primary lesions 
were evaluated according to the standard WHO criteria (18) and evaluation 
criteria proposed by the Japanese Gastric Cancer Association (19). All patients 
were followed for at least one year from their registration in the study. Survival 
was calculated from the date of registration to the date of death from any cause 
or to the last confirmation of survival. TTP was counted from the date of 
registration to the date of confirming disease progression, firstly by image 
diagnosis, secondly by clinical diagnosis, or to the date of death in patients 
without confirmation of disease progression. All clinical information was 
obtained from the JCOG data center. 
 
Statistical analysis 
Survival curves were calculated by the Kaplan-Meier method and 
compared with the log rank test. Patient characteristics and response rates 
were compared with a chi-squared test. 
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Results 
 
Patient characteristics 
Patient characteristics are given in Table I. The subjects constituted two 
thirds of all patients enrolled in JCOG9205. The numbers of patients treated 
with 5-FUci and FP were almost equal. The two groups were well balanced in 
age, sex, macroscopic type, histological type, and history of resection of the 
primary lesions, but there were more patients with poor performance status in 
the FP group than in the 5-FUci group (p=0.0242). Seventeen patients (26%) in 
the 5-FU group and 10 (15%) in the FP group had distant metastasis 
(p=0.1196). 
 
Overall survival and time to progression 
Figure 1 shows the overall survival times of all subjects treated with 
5-FUci or FP. There was no difference in survival between those treated with 
5-FUci or with FP, with median survival times of 216 days in the 5-FUci group 
and 253 days in the FP group (p=0.6953). TTP was longer after FP treatment 
than after 5-FUci treatment (median TTP: 111 days and 61 days, respectively; 
p=0.0477). 
 
Expression of biological markers and response 
The staining pattern and positive rate for each biological marker was 
similar to our previous study (Table II). Table III shows the relationship between 
each biological marker and the chemoresponse. The overall response rates in 
the FP and 5-FUci groups were 44% (29/66) and 12% (8/65), respectively. 
Although the response rates of the patients with VEGF (-) were higher than 
those with VEGF (+) in the 5-FUci group (p=0.0599), there were no differences 
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in response rates between the other markers, (+) or (-), in either the 5-FUci or 
FP groups. 
In the FP treatment group, 11 of the 20 patients (55%) with four or five 
favorable phenotypes, and 18 of the 46 patients (39%) with three or fewer, were 
responders (p=0.2326). However, there was no difference in the response rates 
between the 16 patients with four or five favorable phenotypes and the other 49 
patients in the 5-FUci treatment group (favorable, 2/16 (13%); others, 6/49 
(12%); p>0.9999). 
 
Number of favorable phenotypes, survival, and time to progression 
The 20 patients with four or five favorable phenotypes survived longer 
than the 46 patients with three or fewer in the FP treatment group (MST, 334 
and 243 days, respectively; p=0.0463) (Fig. 2A), whereas there was no 
difference between the two types of patients in the 5-FUci group (MST, 203 and 
216 days, respectively; p=0.315) (Fig. 2B). No significant differences were 
observed in TTP between the patients with four or five favorable phenotypes 
and the other patients either in the FP or the 5-FUci (FP: favorable, 118 days; 
others, 102 days; p=0.2766, and 5-FUci: favorable, 41 days; others, 61 days; 
p=0 .6830). 
 
VEGF, survival, and time to progression 
Either in the 5-FUci or FP group, there was no significant difference in 
survival times between patients with (+) and (-) values in any of p53, bcl-2, TS, 
GST- π individually. As for VEGF, the survival times of the 32 (49%) patients 
with VEGF (+) and the 34 (51%) with VEGF (-) were identical in the FP 
treatment group (MST: 269 and 253 days, respectively; p=0.6317) (Fig. 3A), 
whereas the 30 patients with VEGF (+) showed shorter survival times than the 
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35 with VEGF (+) in the 5-FUci treatment group (MST: 142 and 302 days, 
respectively; p=0.0043) (Fig. 3B). In the FP group, there was no difference in 
TTP between patients with VEGF (+) and those with VEGF (-) (median TTP: 
111 days and 123 days, respectively; p=0.3497). However, the TTP for patients 
with VEGF (-) was significantly longer than the TTP for patients with VEGF (+) 
in the 5-FUci group (median TTP: 101 days and 36 days, respectively; 
p=0.0046). 
 
 
Discussion 
 
The recruitment rates of patients into the present study from the phase 
III study (JCOG9205) were equal in the three regimens. Patient characteristics 
and a positive rating for each biological marker were well balanced. These data 
indicate that biopsy samples were collected without any bias. The overall 
response rates, survival times, and TTP were very similar to the results of all 
enrolled patients to the phase III study (11). Although biopsy specimens were 
collected from only two thirds of the patients in JCOG9205, it is considered that 
the subjects of this study could represent the phase III study well. 
Biopsy samples can be taken only from the superficial part of primary 
tumors and may not represent the biological behavior of the whole tumor 
exactly.  Since many patients to be treated with chemotherapy are 
unresectable, only biopsy samples can be used to assess the biological 
markers. Takiuchi (20) and we (17) have reported that VEGF (+) is a predictive 
marker of chemoresponse in advanced gastric cancer patients treated with FP. 
Nagashima (21) reported that patients with VEGF (+) who were treated with a 
combination of irinotecan (CPT-11) and CDDP showed a higher response rate 
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than those with VEGF (-). These results suggest that assessment of biological 
markers in endocopical biopsy samples can yield useful information and that 
the expression of VEGF in the biopsy samples of gastric cancer patients might 
be a predictor of chemotherapeutic effects in regimens including CDDP. 
The occurrence of positive VEGF was 47% (62/131) in the present 
study, which recapitulated the result of our previous study (51%, 20/39). The 
occurrence of other biological markers was also similar. These results 
implicated that the method for evaluating biological markers in this study was 
reproducible. In the present study there was no relationship between the 
expression of VEGF and chemoresponse to FP treatment while the response 
rates between patients with four or five favorable phenotypes was slightly 
higher than those with three or fewer. It is considered that these discrepancies 
are due to the following differences in the evaluation of responses between our 
previous study and the present study. Firstly, whereas patients in the previous 
study were recruited from a phase II study in which the primary endpoint was 
the response rate, the present study drew subjects from a phase III study in 
which survival time was the primary endpoint. Secondly, while all patients in the 
phase II study had primary tumors by which to evaluate the overall response to 
treatment, 33 of 131 (25%) patients had undergone gastrectomy before the 
initiation of chemotherapy in the phase III study. Thirdly, while a small number 
of institutions participated in the earlier phase II study, patients were enrolled 
from many institutions in the later phase III study. 
In this study, the 20 patients with four or five favorable phenotypes 
survived longer than the other 46 patients with three or fewer in the FP group. 
This result recapitulates our previous findings on survival obtained from the 
phase II study. In the 5-FUci treatment group, there was no difference in 
survival between the two phenotype groups. However, either in the subset of 
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patients with four or five favorable phenotypes nor in those with three or less, 
the differences in survival between the FP and 5-FUci treatments were small. 
Moreover, there were no significant differences in TTP between favorable 
patients and others either in the FP or 5-FUci treatment groups. These results 
suggest that the number of favorable phenotypes may be a prognostic marker 
in patients treated with FP but not a selective marker between FP and 5-FUci. 
VEGF promotes angiogenesis and the permeability of blood vessels 
and is associated with microvessel counts and metastasis (22-23). It has been 
reported that VEGF is a marker of poor prognosis after surgical resection in 
various kinds of malignancies including gastric cancer (24-30). Our previous 
study showed no differences in survival between patients with VEGF (+) and (-) 
despite a higher response rate in those with VEGF (+). Similarly, in the present 
study there were no differences in survival or TTP between patients with VEGF 
(+) or (-) after treatment with FP. However, in the 5-FUci group patients with 
VEGF (+) showed significantly a shorter survival time and TTP than those with 
VEGF (-). Thus, VEGF is considered to be a risk factor for a poor prognosis in 
patients treated with 5-FUci alone. It is suggested that additional cisplatin to 
5-FUci might overcome the malignant potential of VEGF although relationship 
between VEGF and the chemoresponse to FP (17, 20) was not so clear in the 
present study. 
In the phase III study (JCOG9205) (11), FP treatment showed no 
survival benefit over treatment with 5-FUci, although the response rate and TTP 
after FP treatment was significantly better than after 5-FUci. This study showed 
that in the subset of patients with VEGF (-), 5-FUci treatment produced slightly 
longer survival times than FP, and the TTPs were identical. In contrast, in the 
subset of patients with VEGF (+), both survival and TTP of the patients treated 
with FP were longer than those with 5-FUci. These results suggest that VEGF 
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might be a selective marker between FP and 5-FUci. 
In conclusion, the number of favorable phenotypes ( >= 4 or <= 3) out of 
the markers VEGF (+), p53 (-), bcl-2 (-), TS (-), and GST- π (-) was a prognostic 
factor in advanced gastric cancer treated with FP. VEGF might be a selective 
marker to choose FP or 5-FUci. Although the methodology for evaluating 
biological markers in this paper might be immature compared to the present 
one such as microarray or proteomics, we could learn some lessens from the 
present study; 1) not a single markers cannot be prognostic and investigation of 
many markers is necessary especially for cytotoxic agents, 2) confirmation 
should be indispensable, 3) comparison in the phase III study is necessary to 
clarify the utility for selecting treatments. In near future, a clinical study 
investigating the usefulness of biological markers to select an appropriate 
chemotherapy is warranted. 
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Figure 1: Survival curves of patients treated with 5-FUci and FP 
Overall survival of 66 patients treated with FP (    ) and 65 treated with 5-FUci 
(・・ ). 
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 Figure 2: Number of favorable phenotypes and survival 
Overall survival of patients (    ) with 4 or 5 favorable phenotypes out of VEGF 
(+), TS (-), p53 (-), bcl-2 (-), GST- π (-), and those (    ) with 3 or fewer, after 
treatment with FP (A) or 5-FUci (B). 
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 Figure 3: Expression of VEGF and survival 
Overall survival of patients (    ) with VEGF (+), and those (    ) with VEGF (-) 
after treatment with FP (A) or 5-FUci (B). 
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